Lonza Group, CH0013841017

Lonza Group stock: CMS license expands NeuroPortal reach

Published on 11/21/2026 at 12:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lonza Group stock is in focus after a global NeuroPortal license agreement with CMS. The deal adds commercial rights for up to two neurodegenerative disease products.

Lonza expands NeuroPortal commercial reach

  • Lonza granted CMS exclusive global rights for up to two NeuroPortal products targeting neurodegenerative diseases.
  • The agreement combines upfront, development and commercial milestone payments with royalties on net sales.
Lonza Group, CH0013841017, Illustration mit AI erstellt.

Lonza and China Medical System Holdings Limited announced a global exclusive license agreement on November 16, 2026, covering Lonza's NeuroPortal TfR1 blood-brain barrier technology. The agreement gives CMS rights for up to two products targeting neurodegenerative diseases, while Lonza retains licensing options for other therapeutic programs.

The announcement came during a week in which investors also had a fresh commercial development to assess in Lonza's platform business. The technology is designed to help biologic medicines cross the blood-brain barrier, a longstanding challenge in central nervous system drug development.

License terms link technology to milestones

Under the agreement, Lonza will receive an upfront payment, development and commercial milestone payments, and royalties on net sales. The company did not disclose the financial amounts or milestone conditions in its announcement.

CMS receives exclusive rights for the agreed product targets. Lonza said NeuroPortal TfR1 offers binding variants with different affinities, allowing developers to evaluate receptor engagement, transport across the blood-brain barrier and brain exposure for individual therapeutic molecules.

The agreement is the first license Lonza has granted for the newly acquired platform, according to the company's November 16 announcement. Detailed platform results were scheduled for presentation at the Protein and Antibody Engineering Summit in Lisbon from November 16 through November 19.

Lonza stock trades at 705.00 euros

Lonza Group stock last traded at 705.00 euros on Lang & Schwarz at 12:18 CET on Saturday, November 21, 2026.

Lonza Group facts

  • Company: Lonza Group
  • ISIN: CH0013841017
  • Quote: 705.00 euros on Lang & Schwarz at 12:18 CET on November 21, 2026
  • License partner: China Medical System Holdings Limited

Swiss equities remain the relevant market backdrop for Lonza. Current market reports provide the broader view.

More news and analyses on Lonza Group stock

Disclaimer...
en | CH0013841017 | LONZA GROUP | boerse | 70542457 | bgmi